Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Cancer immunotherapy

γδ T cells mediate immunotherapy responses when cancers lack MHC class I

Nature Reviews Immunology volume 23, page 137 (2023)Cite this article

Subjects

Immunotherapy using immune checkpoint blockade (ICB) is considered to mainly benefit patients by activating anti-tumour CD8+ T cell responses. A recent study in Nature shows that γδ T cells are also potently activated by ICB and that subsets of PD1+ Vδ1 and Vδ3 T cells are particularly important for responding to ICB in cancers that have downregulated MHC class I expression.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

Original article

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Immunology http://www.nature.com/nri/

    Yvonne Bordon

Authors
  1. Yvonne Bordon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yvonne Bordon.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bordon, Y. γδ T cells mediate immunotherapy responses when cancers lack MHC class I. Nat Rev Immunol 23, 137 (2023). https://doi.org/10.1038/s41577-023-00842-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41577-023-00842-4

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing